

OFFICE OF THE MEDICAL EXAMINER
COUNTY OF COOK, ILLINOIS
TOXICOLOGY REPORT

Page 1 of 1

AMENDED

M.E. Case: ME2014-01071
Deceased Name: McDonald, Laquan
Autopsy Date: 10/21/2014
Report Date: 03/31/2015
Pathologist: MEANS, DENIKA

Tox Case: 14-3614
Gender: Male
Race: Black
Age: 17

Confirmed Positives

<u>Sample #</u>	<u>Analyte</u>	<u>Sample Type</u>	<u>Methodology</u>	<u>Result</u>	<u>Foot note</u>
01-01	ETHANOL	Hospital Specimens	GC_GC	Negative	(1)

Screen

<u>Sample #</u>	<u>Analyte</u>	<u>Sample Type</u>	<u>Methodology</u>	<u>Result</u>
01-01	BENZOYLECGONINE	Hospital Specimens	ELISA	Negative
01-01	ETHANOL	Hospital Specimens	GC	Negative
01-01	OPIATES	Hospital Specimens	ELISA	Negative
01-05	PHENCYCLIDINE	URINE	ELISA	Positive
01-10	PHENCYCLIDINE	CAVITY BLOOD	ELISA	Positive
01-01	PHENCYCLIDINE	Hospital Specimens	ELISA	Positive

Subcontracted Tests

<u>Test Name</u>	
Phencyclidine NMS	See NMS Report for Result
Risperidone NMS	See NMS Report for Result
Valproic Acid LabCorp	See LabCorp Report for Result

Comments



AMENDED BY: WAGNER, MICHAEL

Toxicologist

Date reviewed: 03/31/2015

Footnotes

1 Quantitation by GC. Confirmation by GC

Test Panels

Opiate ELISA Screen includes: Morphine, Codeine



NMS Labs

CONFIDENTIAL

3701 Welsh Road, PO Box 433A, Willow Grove, PA 19090-0437
Phone: (215) 857-4900 Fax: (215) 857-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Toxicology Report

Report Issued 03/18/2015 13:00

To: **10075**
Cook County Medical Examiner
Attn: Kathleen Mittel
2121 West Harrison Street
Chicago, IL 60612

Patient Name MCDONALD, LAQUAN
Patient ID ME2014-01071 14-3614
Chain 11851876
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15059306

Page 1 of 2

Positive Findings:

<u>Compound</u>	<u>Result</u>	<u>Units</u>	<u>Matrix Source</u>
Phencyclidine	56	ng/mL	001 - Cavity Blood

See Detailed Findings section for additional information

Testing Requested:

<u>Analysis Code</u>	<u>Description</u>
4105B	Risperidone and Metabolite, Blood
8761B	Phencyclidine, Blood

Specimens Received:

<u>ID</u>	<u>Tube/Container</u>	<u>Volume/ Mass</u>	<u>Collection Date/Time</u>	<u>Matrix Source</u>	<u>Miscellaneous Information</u>
001	Red Top Tube	5.5 mL	Not Given	Cavity Blood	

All sample volumes/weights are approximations.
Specimens received on 03/02/2015.



CONFIDENTIAL

Workorder 15059306
Chain 11851876
Patient ID ME2014-01071 14-3614

Page 2 of 2

Detailed Findings:

Analysis and Comments	Result	Units	Rpt. Limit	Specimen Source	Analysis By
Phencyclidine	56	ng/mL	5.0	001 - Cavity Blood	GC/MS

Other than the above findings, examination of the specimen(s) submitted did not reveal any positive findings of toxicological significance by procedures outlined in the accompanying Analysis Summary.

Reference Comments:

1. Phencyclidine (Angel Dust; PCP; Sherm) - Cavity Blood:

Phencyclidine (PCP) is a DEA Schedule II controlled dangerous hallucinogenic drug. There exists a dearth of pharmacokinetic data of PCP usage in humans; however it has been reported that blood levels of phencyclidine ranged from 7 - 240 ng/mL (mean, 75 ng/mL) in individuals stopped for driving under the influence of drugs or for being intoxicated in public.

Ataxia, agitation, combativeness, seizures, spasticity, coma and respiratory depression are associated with phencyclidine concentrations ranging from 90 - 220 ng/mL plasma.

The physiological effects of PCP can be classified as low or high dose. In low doses, PCP can elicit visual disturbances, drowsiness, agitation, hallucinations, aggressiveness, increased pulse rate and blood pressure, bronchospasm, increased respiratory rate and hyperthermia. In high doses, PCP can elicit convulsions, opisthotonos, coma, arrhythmias, decreased blood pressure and respirations and rhabdomyolysis.

There appears to be no relation between plasma levels of phencyclidine and degree of intoxication. Even so, death has been reported following the use of only 120 mg of phencyclidine. Blood concentrations in phencyclidine-related fatalities have been reported to range from 300 - 25000 ng/mL (mean, 5000 ng/mL).

Unless alternate arrangements are made by you, the remainder of the submitted specimens will be discarded one (1) year from the date of this report; and generated data will be discarded five (5) years from the date the analyses were performed.

Analysis Summary and Reporting Limits:

All of the following tests were performed for this case. For each test, the compounds listed were included in the scope. The Reporting Limit listed for each compound represents the lowest concentration of the compound that will be reported as being positive. If the compound is listed as None Detected, it is not present above the Reporting Limit. Please refer to the Positive Findings section of the report for those compounds that were identified as being present.

Acode 4105B - Risperidone and Metabolite, Blood - Cavity Blood

-Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
9-Hydroxyrisperidone	1.0 ng/mL	Risperidone and 9-Hydroxyrisperidone - Total	N/A
Risperidone	1.0 ng/mL		

Acode 8761B - Phencyclidine, Blood - Cavity Blood

-Analysis by Gas Chromatography/Mass Spectrometry (GC/MS) for:

Compound	Rpt. Limit	Compound	Rpt. Limit
Phencyclidine	5.0 ng/mL		